Senior Management

Martin Whitaker, BSc PhD - Chief Executive Officer

Martin has over 20 years’ experience in the pharmaceutical industry and has led the Diurnal team since 2008. Previously, Martin worked with Fusion IP plc (now IP Group plc) with responsibility for commercialising research from the University of Sheffield. Prior to this, Martin was Operations Director of Critical Pharmaceuticals, a venture capital-backed drug delivery company developing long-acting growth hormone products. Martin is also a Director of D3 Pharma Ltd, which successfully commercialised Plenachol®, a high dose Vitamin D product. Martin has a PhD in Pharmaceutical Science from the University of Nottingham and a BSc (Hons) in Biochemistry from Bristol University. He is Honorary Professor of Medical Innovation at the University of Sheffield.

... Show more

Richard Bungay, BSc ACA - Chief Financial Officer

Richard has over 25 years’ experience in senior finance and strategic roles within the pharmaceutical and biotechnology sector. His prior experience includes CFO and COO of Mereo BioPharma, CFO of Glide Technologies, CFO of Verona Pharma, CEO (formerly CFO) of Chroma Therapeutics, Director of Corporate Communications and Strategic Planning at Celltech and Finance Director of the Respiratory and Inflammation therapy area at AstraZeneca. Richard is also a Non-Executive Director of Cambridge Cognition Holdings plc and Chroma Therapeutics Limited. He qualified as a Chartered Accountant with Deloitte and has a first class degree in Chemistry from Nottingham University.

... Show more

Richard Ross, MBBS MD FRCP - Chief Scientific Officer

Richard is a founding Director of Diurnal. He is a Professor of Clinical Endocrinology and Head of the Academic Unit of Diabetes, Endocrinology and Metabolism at the University of Sheffield and was previously a Senior Lecturer at St. Bartholomew’s Hospital, London. Richard’s primary research interest is pituitary and adrenal disease with a particular focus on hormone replacement. His research has yielded over 200 papers, more than 30 granted patents and publications in Nature Medicine, Nature Reviews Endocrinology, Nature Genetics, The Lancet, The BMJ and PNAS. He has been a member of the editorial boards of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism and served as an elected member of the executive committees for the European Society of Endocrinology (Treasurer), the Society for Endocrinology, the Growth Hormone Research Society and the Pituitary Society. Richard is also a Director of Asterion Limited.

... Show more

Michael Withe - Commercial Director

Michael Withe is Commercial Director at Diurnal with responsibility for delivering the Group’s commercial objectives. Michael has over 25 years’ experience in the pharmaceutical industry specifically Orphan Drugs and Speciality pharmaceuticals. Previously, Michael worked for Chiesi as Head of Rare Diseases with responsibility for the creation of the Global Rare Disease Franchise and commercialising the first gene therapy and Limbus Stem Cell transplantation in the western world. Prior to this, Michael worked in the area of Lysosomal Storage Disorders for Shire and BioMarin. Michael is a microbiologist with a background with a postgraduate qualification in marketing.

... Show more

John Porter, MBBS PhD - Medical Director

John Porter is Medical Director at Diurnal. John is a paediatric endocrinologist and has 10 years’ experience in the pharmaceutical industry. Previously, John had medical director roles at Pfizer, Novartis and GSK covering a wide portfolio of medicines in therapy areas including endocrinology, haematology, infectious disease and vaccines. John studied medicine at Oxford and Newcastle-upon-Tyne Universities, qualifying in 1995. He trained in paediatric endocrinology and diabetes and has a PhD in the genetics of paediatric diabetes.

... Show more

Stewart Jones - Product Development Director

Stewart has over 25 years’ experience in CMC and programme management, spanning the fine chemicals, CMO, Biotech and BioPharmaceutical industries. Stewart’s responsibility is to ensure that all of Diurnal’s development programmes are fully integrated and to manage their progress through to successful conclusion. Prior to joining Diurnal, Stewart was at AIM listed Mereo BioPharma as Head of CMC and oversaw all manufacturing activities. Before Mereo, Stewart was at Chroma Therapeutics for over 9 years and was responsible for the development of the clinical portfolio, all of which have been successfully licensed on. Previously Stewart worked in the development department at Evotec (now Aptuit) for 9 years leading teams on the manufacturing development of several different therapeutic entities from small molecules to large molecules, peptides and liquid crystals, some of which have subsequently gone on to commercial launch. Stewart has a BSc (hons) in chemistry.

... Show more

Diurnal Group plc (Company Number: 09846650) is registered in England & Wales. Registered office: Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ, UK.